Evidence map›Paper›PMID 39752321›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2025

Integration of the rat liver micronucleus assay into a 28-day treatment protocol: testing the genotoxicity of 4 small-molecule nitrosamines with different carcinogenic potencies and tumor target specificities.

Xiaoqing Guo, Ji-Eun Seo, Hannah Xu, Jian Yan, Pritpal Malhi, Aisar H Atrakchi, Timothy McGovern, Karen L Davis Bruno, Robert H Heflich, Tao Chen

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mutation accumulation following extended exposure of human HepaRG cells to a genotoxic carcinogen.Journal of environmental science and health. Part C, Toxicology and carcinogenesis · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoqing GuoNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.ORCID 0000-0001-5951-2156
Ji-Eun SeoNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Hannah XuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Jian YanNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Pritpal MalhiToxicologic Pathology Associates, Jefferson, AR 72079, United States.
Aisar H AtrakchiCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, United States.
Timothy McGovernCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, United States.ORCID 0009-0006-9232-6041
Karen L Davis BrunoCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, United States.
Robert H HeflichNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Tao ChenNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.

Funding

Center for Drug Evaluation and ResearchIntramural FDA HHS FD999999NCTROffice of New Drugs Regulatory Science Research Program
6 · The paper itself

Abstract

Several potent carcinogenic nitrosamines, including N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA), induce micronuclei in the micronucleated hepatocyte (MNHEP) assay but not in the micronucleated reticulocyte (MNRET) assay. However, the MNHEP assay is not as frequently used as the MNRET assay for evaluating in vivo genotoxicity. The present study evaluated MN formation in the liver of Big Blue transgenic rats exposed to 4 small-molecule nitrosamines, NDMA, N-nitrosodiisopropylamine (NDIPA), N-nitrosoethylisopropylamine (NEIPA), and N-nitrosomethylphenylamine (NMPA), using a repeat-dose protocol typically used for in vivo mutagenicity studies. NDMA is a potent liver carcinogen, whereas NDIPA and NEIPA are relatively weak liver carcinogens, and NMPA primarily produces esophageal tumors. Seven-week-old rats were treated with the nitrosamines for 28 consecutive days; liver was harvested 3 days after the last dose and used for conducting the flow-cytometry-based MNHEP assay. All 4 nitrosamines induced dose-dependent increases in %MNHEP and the magnitude of the responses correlated with their carcinogenicity in rat liver. These results indicate that the flow-cytometry-based MNHEP assay can be successfully integrated into 28-day repeat-dose studies, and that the MNHEP assay may be useful for evaluating the genotoxicity of nitrosamines that have different carcinogenic potencies and different tumor target specificities.

Indexed as

CarcinogensLiverNitrosaminesAnimalsDose-Response Relationship, DrugHepatocytesMaleMicronucleus TestsRatsRats, TransgenicReticulocytesCarcinogensNitrosaminesbenchmark dosein vivolivermicronucleus assaynitrosamines

Identifiers

PMID39752321
PMCPMC12442842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.